Table 2 COX multivariate analysis of JAM3 methylation status with 5-year survival in EC patients (n = 237)
From: Epigenetic silencing of JAM3 promotes esophageal cancer development by activating Wnt signaling
Clinical parameter | HR (95%CI) | p value |
|---|---|---|
Gender (male vs. female) | 1.336 (0.768–2.326) | 0.305 |
Age (≥ 60 vs. < 60 years) | 1.462 (0.932–2.293) | 0.099 |
Tumor size (≥ 4 vs. < 4 cm) | 1.143 (0.756–1.727) | 0.527 |
Differentiation (low vs. high or middle) | 1.354 (0.891–2.057) | 0.156 |
TNM stage (3–4 vs. 1–2) | 1.276 (0.504–3.231) | 0.607 |
Lymph node metastasis (positive vs. negative) | 1.572 (0.597–4.141) | 0.360 |
JAM3 (methylation vs. unmethylation) | 1.545 (1.019–2.343) | 0.041* |
Smoking (yes vs. no) | 0.858 (0.523–1.407) | 0.544 |
Drinking (yes vs. no) | 1.381 (0.869–2.195) | 0.172 |
family history (yes vs. no) | 0.785 (0.520–1.184) | 0.248 |